Home › Hologic to Divest Stake in Blood Screening Business to Grifols for $1.85B

Hologic to Divest Stake in Blood Screening Business to Grifols for $1.85B

Dec 14, 2016

NEW YORK (GenomeWeb) – Hologic announced after the close of the market on Wednesday that it will sell its share of a blood screening business to Grifols, its commercial partner, in a deal worth $1.85 billion in cash.

The boards of directors of both companies have approved the deal.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Molecular Diagnostics

  1. Cancer Genetics Cancels Planned Merger With NovellusDx

  2. Mobidiag, Autobio Diagnostics to Form Joint Venture in China

  3. Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs

  4. Curetis to Cut 30 Percent of Workforce as Part of Strategic Restructuring

  5. Black Women With Breast Cancer Fare Worse, TAILORx Analysis Confirms at SABCS

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.